title: Antisolvent crystallisation is a potential technique to prepare engineered lactose with promising aerosolisation properties: effect of saturation degree.
abstract: Engineered lactose particles were prepared by anti-solvent crystallisation technique using lactose solutions with different saturation degrees. In comparison to commercial lactose, engineered lactose particles exhibited less elongated and more irregular shape (large aggregates composed of smaller sub-units), rougher surface texture, higher specific surface area, and different anomer form. Engineered lactose powders demonstrated smaller bulk density, smaller tap density, and higher porosity than commercial lactose powder. Dry powder inhaler (DPI) formulations containing engineered lactose and salbutamol sulphate as a model drug demonstrated improved drug content homogeneity and higher amounts of drug delivered to lower airway regions. Higher fine particle fraction of drug was obtained in the case of lactose powders with higher porosity, higher specific surface area and higher fine particle content (<5 μm). The results indicated that the higher the saturation degree of lactose solution used during crystallisation the smaller the specific surface area, the higher the amorphous lactose content, and the higher the β-lactose content of engineered lactose particles. Also, lactose powders obtained from lactose solution with higher degree of saturation showed higher bulk and tap densities and smaller porosity. Engineered lactose powders crystallized from lower saturation degree (20% and 30% w/v) deposited higher amounts of drug on lower airway regions. In conclusion, this study demonstrated that it is possible to prepare engineered lactose particles with favourable properties (e.g. higher fine particle fraction and better drug content homogeneity) for DPI formulations by using lactose solutions with lower degree of saturation during crystallisation process.
authors.affiliation: Chemistry and Drug Delivery Group, Medway School of Pharmacy, University of Kent, ME4 4TB, Kent, UK. waseemkaialy@hotmail.co.uk
authors.forename: Waseem
authors.initials: W
authors.lastname: Kaialy
authors.forename: Ali
authors.initials: A
authors.lastname: Nokhodchi
mesh_terms: D020001:1-Butanol / Q000737:chemistry; D000336:Aerosols; D000420:Albuterol / Q000737:chemistry; D001993:Bronchodilator Agents / Q000737:chemistry; D003460:Crystallization; D004339:Drug Compounding / Q000379:methods*; D058995:Dry Powder Inhalers; D000431:Ethanol / Q000737:chemistry; D007785:Lactose / Q000737:chemistry*; D010316:Particle Size; D012997:Solvents / Q000737:chemistry
chemical_list: D000336:Aerosols; D001993:Bronchodilator Agents; D012997:Solvents; D000431:Ethanol; D020001:1-Butanol; D007785:Lactose; D000420:Albuterol